Note: Descriptions are shown in the official language in which they were submitted.
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 1 -
Composition for ophthalmological products
Description
Technical area
The present invention relates to a composition for ophthalmological prod-
ucts, to corresponding copolymers and the preparation of and to the use
thereof for the production of ophthalmic lenses or ophthalmological implants
and to these products
Prior art
Cataract denotes pacification of the ocular lens which leads to slow, pain-
less loss of visual acuity, in particular if the opacification starts in the
central
region of the lens. Those affected perceive their environment "like through
fog". The opacified lens can in most cases be replaced surgically by a syn-
thetic lens implant, so-called intraocular lenses (10Ls).
A multiplicity of intraocular lenses is known. An intraocular lens is con-
structed, for example, from a central optical lens and the peripherally
attached haptic, which fixes the optical lens in the eye. The haptic can have
various shapes, for example C-loop haptics or plate haptics. On the basis of
the material, the lenses can be divided into hard, non-foldablel0Ls and
soft, foldablel0Ls. The hard lenses consist of polymethyl methacrylate.
Foldable lenses consist of acrylates, siloxanes or hydrogels. The advantage
of foldable lenses essentially consists in that a smaller incision is
necessary
for the implantation. A new form of intraocular lens is the light-adjustable
lens (LAL). In the case of the LAL, the lens power can be adjusted after the
operation by irradiation with light of suitable wavelength, for example UV
light.
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 2 -
A phakic intraocular lens (PIOL) is an artificial lens which is implanted into
the eye in addition to the natural lens. Phakic intraocular lenses can be im-
planted as part of correction of defective vision. A PIOL is constructed from
the central optical lens and the peripherally adjacent haptic, which fixes the
optical lens in the eye. On the basis of the localisation of the PIOL in the
eye, a distinction is made between anterior chamber and posterior chamber
lenses. The anterior chamber lens is implanted between cornea and iris,
the posterior chamber lens between iris and ocular lens. Anterior chamber
lenses consist either of hard polymethyl methacrylate or soft materials,
such as silicone or acrylic compounds. Posterior chamber lenses are gen-
erally made from soft materials.
A light-adjustable lens can consist, for example, of siloxanes which contain
radicals that are photochemically active in the UV range. If the LAL is irradi-
ated with UV light, the polymers change their structure. The first light-
adjustable lens was developed in 1999 by the American ophthalmologist
Dr. Daniel Schwarz and Robert Grubbs (Daniel M. Schwartz et al, Light-
adjustable lens: development of in vitro nomograms; in Transactions of the
American Ophthalmological Society Vol 102, December 2004, 67-74.)
The development of suitable materials forIOLs has advanced rapidly.
US 8,247,511, for example, describes the production of an intraocular lens
in which a rigid copolymer is prepared from a first monomer selected from
the group of ethylene glycol phenyl ether acrylate (EGPEA) and poly-
ethylene glycol phenyl ether acrylate [(poly-EG)PEA], a second monomer
from the group of the unsubstituted or substituted styrenes and a third
monomer containing an ethylenically unsaturated group which would form a
hydrogel as homopolymer, a rigid intraocular lens is formed, and this is con-
verted into a foldable intraocular lens by hydration, where the lens has a
refractive index of about 1.50.
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
- 3 -
Artificial intraocular lenses which are formed from a polymer material which
contains photochemically activatable groups, so that a photoinduced modifi-
cation of the optical properties of the artificial intraocular lens can be
carried
out, are known, for example, from EP 1926454.
M. Schraub et al, European Polymer Journal 51 (2014) 21-27, describes,
for example, the photochemistry of polymethacrylates containing 3-phenyl-
coumarine.
WO 2017/032442, WO 2017/032444 and WO 2017/032443 describe mate-
rials for the production of medical devices, preferably ophthalmological
products, particularly preferably for the production of intraocular lenses.
These materials can preferably be used as photoactive monomers in the
preparation of suitable polymers or copolymers of the products.
Both hydrophobic, soft acrylate polymers and siloxane polymers, which are
known for use for the production of intraocular lenses, exhibit glistening.
The tendency towards glistening is more pronounced in the first-mentioned
polymers. According to A. Miyata and S. Yaguchi, J Cataract Refract Surg
2004; 30:1768-1772, glistening is a phase-separation phenomenon that
occurs in the case of temperature variations as soon as the polymer is
located in an aqueous environment, as is the case in the human eye. The
water content of the polymer increases with the temperature. In the case of
a temperature drop, the water absorption capacity of the polymer falls,
causing phase separation. The polymer phase here has a different refrac-
tive index to the water phase, causing the water phase in the form of vacu-
oles to be perceived as glistening. The degree of glistening is crucially
determined by the temperature dependence of the water content of the
polymer. The greater the temperature dependence, the more severe the
glistening-induced visual impairment of the patient can be.
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
- 4 -
The water content of a polymer can be increased by addition of a hydro-
philic component during the polymerisation. A hydrophilic component is a
monomer whose uncrosslinked homopolymer is water-soluble or swellable
in water. A crosslinked copolymer which contains a hydrophilic component
can be, for example, a hydrogel. Such hydrogels form a further class of
ophthalmological materials, namely hydrophilic acrylate polymers. These
are rigid in the dry state and become soft after swelling in water, as known,
for example, from US 8,247,511 and Bozukova D et al, Mat. Sci. Eng. 2010,
69:63-83.
The water content of such polymers is greater than 10 per cent by weight. If
the water content of a swollen polymer of this type is greater than 10 per
cent by weight, the term hydrophilic polymer can be used.
In contrast to hydrophobic acrylate polymers, hydrogels do not exhibit glis-
tening, but calcification occurs in them, as described in Trivedi et al, Eye
2002, 16: 217-241. Calcification refers to calcium compounds which
deposit principally on the lens surface and cloud the vision.
Consequently, there are two phenomena, namely glistening and calcifica-
tion, that are undesired and occur in the case of excessively low or exces-
sively high hydrophilicity of the polymeric material respectively.
The object of the present invention is the provision of a suitable polymeric
material containing specific photoactive polymerised monomers which is
soft and shapable at an ambient temperature between 16 C and 18 C and
exhibits little glistening or no glistening and at the same time is
sufficiently
hydrophobic that calcification cannot occur, and the corresponding compo-
sition which is suitable for the preparation of this material. The polymeric
material should additionally be transparent and change its refractive index
on exposure to select light of a wavelength X, for example on use of a UV
light source of corresponding wavelength X or on use of a laser having a
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
- 5 -
sufficiently high pulse frequency whose emitted light has wavelength 2 X or
even n X, where n is a natural number. Furthermore, the polymeric material
and the corresponding ophthalmological lens comprising the polymeric
material should have unfolding times of less than 60 seconds, preferably
from 10 to 40 seconds, particularly preferably from 15 to 25 seconds, in an
aqueous environment at 35 C. Unfolding times of known materials are
described, for example, in "The Ophthalmologist, 2017, Issue#1217".
The specific photoactive monomers are known, for example, from
WO 2017/032442 bekannt.
The object is correspondingly achieved by the independent and dependent
claims of the present patent application.
Summary of the invention
It has been found that a suitable choice of monomers in a composition com-
prising specific photoactive monomers leads to the preparation of a cross-
linked transparent copolymer which changes its refractive index due to
exposure to light of corresponding wavelength, has no or virtually no glis-
tening and which, without further hydration, is soft at an ambient tempera-
ture between 16 C and 18 C, so that it can be implanted into an eye, for
example in the form of an intraocular lens, by means of standard applica-
tors in accordance with the prior art. In addition, the polymeric material is
transparent and changes its refractive index on exposure to light of a corre-
sponding wavelength X, for example on use of a UV light source of corre-
sponding wavelength X or on use of a laser having a sufficiently high pulse
frequency whose emitted light has wavelength 2 X or n X. The intraocular
lenses produced from the crosslinked transparent copolymer have advanta-
geous unfolding times.
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
- 6 -
The material preferably has no glistening. The term "no or virtually no glis-
tening" means that the copolymer is always clear and the vacuole number
in accordance with the glistening test, as described here and in Clinical
Ophthalmology, 2013, 7, 1529-1534, is below 100 vacuoles/mm3, prefera-
bly below 25 vacuoles/mm3, particularly preferably below 20 vacuoles/mm3
and very particularly preferably below 10 vacuoles/mm3 or below 5 vacu-
oles/mm3; these values correspond to scale 0 which was introduced by
Akira Miyata. Miyata et al, Jpn J Ophthalmol 2001, 45, 564 ¨ 569, describe
scale 0 with below 50 vacuoles/mm3, the limit of scale 1 with 50 vacuoles/
mm3, the limit of scale 2 with 100 vacuoles/mm3 and the limit of scale 3 with
200 vacuoles/mm3.
The invention therefore relates firstly to a composition comprising specific
photoactive monomers of the formula (1), as described below, at least one
hydrophilic monomer whose uncrosslinked homopolymer is water-soluble
or swellable in water, a UV absorber and a crosslinker, where the molar
ratio of the sum of all compounds of the formula (1) to the sum of all hydro-
philic monomers is 1:0.51 to 1:1.24.
The invention furthermore relates to the use of the composition for the prep-
aration of a corresponding copolymer or for the production of a blank for an
ophthalmic lens or an ophthalmological implant.
The invention furthermore relates to the correspondingly crosslinked co-
polymer, to a process for the preparation of a copolymer of this type and to
the use thereof for the production of an article, preferably a blank for an
ophthalmic lens, a blank for an ophthalmological implant, an ophthalmic
lens or an ophthalmological implant.
The invention furthermore relates to the corresponding article and to the
process for the production of the article.
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 7 -
Description of the invention
The invention therefore relates firstly to a composition comprising at least
one compound of the formula (1)
Ri R5 R6
x y
o /
R12>---Z\
Ri R2 R3 R4
Rio s ID-(X1 )a R7 (1)
R9 R9 ,
where the following applies to the symbols and indices used:
X is on each occurrence, identically or differently, 0, S or NR ;
Y is on each occurrence, identically or differently, 0 or S;
Xi is 0 or S;
a is 0 or 1;
Sp is an alkanediyl, alkenediyl or alkynediyl, which may be
substituted
by one or more groups R;
R is a straight-chain or branched alkyl group having Ito 10 C
atoms;
R1, R2, R3 and R4 are in each case, independently of one another on
each occurrence, H, F, Cl, Br, I, a straight-chain or branched alkyl
group having 1 to 20 C atoms, a partially or fully halogenated
straight-chain or branched alkyl group having 1 to 20 C atoms or an
aryl or heteroaryl group having 5 to 40 ring atoms;
R5, R6, R7, R8 and R9 are in each case, independently of one
another on each occurrence, H, F, Cl, Br, I, a straight-chain or
branched alkyl group having 1 to 20 C atoms, a straight-chain or
branched alkoxy group having 1 to 20 C atoms, a partially or fully
halogenated straight-chain or branched alkyl group having 1 to 20
C atoms, a partially or fully halogenated straight-chain or branched
alkoxy group having 1 to 20 C atoms or an aryl or heteroaryl group
having 5 to 40 ring atoms, where at least one radical from the group
of substituents R5 to R9 denotes a straight-chain or branched alkyl
group having 1 to 20 C atoms, which may be partially or fully halo-
genated;
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 8 -
R10, R11, rc r-,12
are in each case, independently of one another on each
occurrence, H, F, a linear or branched alkyl group having 1 to 20 C
atoms, which may be partially or fully halogenated, or an aryl group
having 6 to 14 C atoms;
R is selected on each occurrence, identically or differently, from the
group consisting of a straight-chain or branched alkyl group having
Ito 10 C atoms, a partially halogenated or fully halogenated
straight-chain or branched alkyl group having Ito 10 C atoms, a
straight-chain or branched alkoxy group having Ito 10 C atoms or
a partially halogenated or fully halogenated straight-chain or
branched alkoxy group having Ito 10 C atoms;
at least one hydrophilic monomer whose uncrosslinked homopolymer is
water-soluble or swellable in water;
at least one UV absorber and at least one crosslinker, where the molar ratio
of the sum of all compounds of the formula (1) to the sum of all hydrophilic
monomers is 1:0.51 to 1:1.24.
The term composition is used below synonymously for the term formulation
or preparation.
The composition can include or comprise, essentially consist of or consist
of the said requisite or optional constituents. All compounds or components
which can be used in the compositions are either known and commercially
available or can be synthesised by known processes, as described, for
example, for the compounds of the formula (1) in WO 2017/032442, pages
21 and 22 and pages 44 to 78. Document WO 2017/032442 is hereby
incorporated into the description by way of reference.
The compounds of the formula (1) and the preferred embodiments thereof,
as described below, include all stereoisomers or racemic mixtures.
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
- 9 -
In general, surfaces are divided into hydrophilic and hydrophobic surfaces
on the basis of their contact angle with water. The following applies: 0 <
contact angle <900 hydrophilic; contact angle > 90 hydrophobic. The con-
tact angle here is the result of surface structure and material (literature:
FOrch, R.; SchOnherr, H.; Tobias, A.; Jenkins, A. See Appendix C. In Sur-
face Design: Applications in Bioscience and Nanotechnology, Wiley-
VCH:Weinheim, Germany, 2009; page 471). Since the division into hydro-
philic and hydrophobic is intended to relate predominantly to the bulk prop-
erties of the polymers and the individual components thereof, the said divi-
sion by means of contact angle is not appropriate.
For the division of intraocular lenses into hydrophilic and hydrophobic
lenses, Bozukova et al indicate their water content as the division criterion.
If this water content is less than 10 - 20% by weight, it is a hydrophobic
intraocular lens; if this water content is greater than 10 - 20% by weight, it
is
a hydrophilic intraocular lens (literature: Bozukova D, Pagnoulle C, Jerome
R, Jerome C, (2010) Polymers in modern ophthalmic implants -Historical
background and recent advances, Material Science and Engineering R
69:63-83). The water absorption of a material is the more appropriate deci-
sion criterion with respect to hydrophilicity and hydrophobicity for the poly-
mers prepared in the context of this invention with respect to their area of
application. For division of monomers into hydrophilic and hydrophobic
monomers, it is useful in the context of this invention and the application
aims thereof to use a division described by Bozukova et al: if a monomer
gives a homopolymer which is either completely water-soluble or has a
water absorption of greater than 10% by weight, this exhibits a hydrophilic
property and is classified as hydrophilic monomer for the purposes of this
invention. The hydrophilic property is caused by functional groups in the
monomer which are capable of binding water molecules. The property can
be confirmed in the swollen state by the presence of non-freezable water.
The non-freezable water here is based on the fact that functional groups in
the polymer bind water per se and this water is therefore not capable of
forming ice crystals, irrespective of the temperature. Unaffected by this, a
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 10 -
polymer of this type may also contain freezable water which forms ice crys-
tals, but this is not utilised for the division into hydrophilic and
hydrophobic
monomers. Examples of functional groups which are capable of binding
non-freezable water are, inter alia, hydroxyl groups, amino groups, ammo-
nium groups, carboxyl groups, sulfone groups, sulfate groups, ether bridges
or amide groups. The presence of functional groups of this type in a mono-
mer is thus an indicator of a hydrophilic monomer.
Therefore, if a monomer satisfies one or more of the said criteria water sol-
ubility of the resultant homopolymer, water absorption of the resultant
homopolymer greater than 10% by weight and/or presence of non-freezable
water in the resultant homopolymer, this is a "hydrophilic monomer" for the
purposes of the invention. If a monomer does not satisfy any of the said cri-
teria, this is referred to as "non-hydrophilic monomer" for the purposes of
the invention.
For the purposes of the present invention, a straight-chain or branched alkyl
group having 1 to 20 C atoms is taken to mean the radicals methyl, ethyl,
n-propyl, i-propyl, cyclopropyl, n-butyl, i-butyl, s-butyl, t-butyl,
cyclobutyl,
2-methyl butyl, n-pentyl, s-pentyl, t-pentyl, 2-pentyl, neopentyl,
cyclopentyl,
n-hexyl, s-hexyl, t-hexyl, 2-hexyl, 3-hexyl, neohexyl, 2-methylpentyl,
n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, n-octyl, 2-ethylhexyl, n-nonyl, n-
decyl,
2-(2,6-dimethyl)octyl, 3-(3,7-dimethyl)octyl, 1,1-dimethyl-n-hex-1-y1-, 1,1-
dimethyl-n-hept-1-y1-, 1,1-dimethyl-n-oct-1-y1-, n-undecyl, n-dodecyl, 1,1-
dimethyl-n-dec-1-y1-, n-tridecyl, n-tetradecyl, 1,1-dimethyl-n-dodec-1-y1-,
n-heptadecyl, n-hexadecyl, 1,1-dimethyl-n-tetradec-1-y1-, n-octadecyl,
n-nonadecyl, 1,1-dimethyl-n-hexadec-1-y1-, 1,1-dimethyl-n-octadec-1-y1-,
1,1-diethyl-n-hex-1-y1-, 1,1-diethyl-n-hept-1-y1-, 1,1-diethyl-n-oct-1-y1-,
1,1-
diethyl-n-dec-1-y1-, 1,1-diethyl-n-dodec-1-y1-, 1,1-diethyl-n-tetradec-1-y1-,
1,1-diethyl-n-hexadec-1-y1-, 1,1-diethyl-n-octadec-1-yl- and n-eicosyl.
Partially halogenated alkyl groups correspond to the straight-chain or
branched alkyl groups having 1 to 20 C atoms, as described above, in
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
-11 -
which at least one H atom has been replaced by a halogen atom, but not all
H atoms have been replaced by halogen atoms. Preferred halogen atoms
are F atoms or Cl atoms, particularly preferably partially fluorinated alkyl
groups, for example 2,2,2-trifluoroethyl.
Fully halogenated alkyl groups correspond to the straight-chain or branched
alkyl groups having 1 to 20 C atoms, as described above, in which all H
atoms have been replaced by the corresponding halogen atom. Preferred
halogen atoms are F atoms or Cl atoms, particularly preferably fully fluori-
nated alkyl groups. Examples thereof are trifluoromethyl, pentafluoroethyl
or nonafluorobutyl.
For the purposes of the present invention, alkanediyl corresponds to a diva-
lent group derived from a straight-chain or branched alkyl group having 1 to
20 C atoms, as described above.
The purposes of the present invention, alkenediyl corresponds to a divalent
group derived from a straight-chain or branched alkenyl group having 1 to
C atoms which corresponds to a straight-chain or branched alkyl group
having 1 to 20 C atoms, as described above, but contains at least one dou-
20 ble bond.
For the purposes of the present invention, alkynediyl corresponds to a diva-
lent group derived from a straight-chain or branched alkynyl group having 1
to 20 C atoms which corresponds to a straight-chain or branched alkyl
group having 1 to 20 C atoms, as described above, but contains at least
one triple bond.
Alkanediyl, alkenediyl or alkynediyl can correspondingly be substituted by
one or more radicals R.
For the purposes of the present invention, a partially halogenated or fully
halogenated straight-chain or branched alkoxy group having 1 to 20 C
atoms corresponds to a partially halogenated or fully halogenated straight-
chain or branched alkyl group having 1 to 20 C atoms, where the alkyl
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 12 -
group described above is correspondingly bonded to an 0 atom and can be
abbreviated to 0-alkyl.
For the purposes of the present invention, a straight-chain or branched thio-
alkyl group having 1 to 20 C atoms corresponds to a straight-chain or
branched alkyl group having 1 to 20 C atoms, where the alkyl group
described above is correspondingly bonded to an S atom and can be
abbreviated to S-alkyl.
A cycloalkyl group containing 3 to 8 C atoms is, for example, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, which may
also in each case be substituted by a radical R.
An aryl group in the sense of this invention contains 6 to 40 aromatic ring
atoms, preferably C atoms. A heteroaryl group in the sense of this invention
contains 5 to 40 aromatic ring atoms, where the ring atoms include C atoms
and at least one heteroatom, with the proviso that the sum of C atoms and
heteroatoms is at least 5. The heteroatoms are preferably selected from N,
0 and/or S. An aryl group or heteroaryl group is taken to mean either a sim-
pie aromatic ring, i.e. phenyl, derived from benzene, or a simple hetero-
aromatic ring, for example derived from pyridine, pyrimidine or thiophene,
or a condensed aryl or heteroaryl group, for example naphthalene, anthra-
cene, phenanthrene, quinoline or isoquinoline.
An aryl or heteroaryl group having 5 - 40 ring atoms, which may also in
each case be substituted by a radical R and which may be linked via any
desired positions on the aromatic or heteroaromatic group, are taken to
mean, for example, the following groups benzene, naphthalene, anthra-
cene, benzanthracene, phenanthrene, benzophenanthrene, pyrene, chrys-
ene, perylene, fluoranthene, benzofluoranthene, naphthacene, pentacene,
benzopyrene, biphenyl, biphenylene, terphenyl, terphenylene, fluorene,
spirobifluorene, dihydrophenanthrene, dihydropyrene, tetrahydropyrene,
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
- 13 -
cis- or trans-indenofluorene, cis- or trans-monobenzoindenofluorene, cis- or
trans-dibenzoindenofluorene, truxene, isotruxene, spirotruxene, spiroiso-
truxene, furan, benzofuran, isobenzofuran, dibenzofuran, thiophene, benzo-
thiophene, isobenzothiophene, dibenzothiophene, pyrrole, indole, isoindole,
carbazole, indolocarbazole, indenocarbazole, pyridine, quinoline, isoquino-
line, acridine, phenanthridine, benzo-5,6-quinoline, benzo-6,7-quinoline,
benzo-7,8-quinoline, phenothiazine, phenoxazine, pyrazole, indazole, imid-
azole, benzimidazole, naphthimidazole, phenanthrimidazole, pyridimid-
azole, pyrazinimidazole, quinoxalinimidazole, oxazole, benzoxazole, naph-
thoxazole, anthroxazole, phenanthroxazole, isoxazole, 1,2-thiazole, 1,3-
thiazole, benzothiazole, pyridazine, benzopyridazine, pyrimidine, benzo-
pyrimidine, quinoxaline, 1,5-diazaanthracene, 2,7-diazapyrene, 2,3-diaza-
pyrene, 1,6-diazapyrene, 1,8-diazapyrene, 4,5-diazapyrene, 4,5,9,10-tetra-
azaperylene, pyrazine, phenazine, phenoxazine, phenothiazine, fluorubin,
naphthyridine, azacarbazole, benzocarboline, phenanthroline, 1,2,3-tri-
azole, 1,2,4-triazole, benzotriazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole,
1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole,
1,2,5-thiadiazole, 1,3,4-thiadiazole, 1,3,5-triazine, 1,2,4-triazine, 1,2,3-
tri-
azine, tetrazole, 1,2,4,5-tetrazine, 1,2,3,4-tetrazine, 1,2,3,5-tetrazine,
purine, pteridine, indolizine and benzothiadiazole.
An arylalkyl group is an alkyl group which is substituted by at least one aryl
group.
An alkylarylalkyl group is an alkyl group which is substituted by at least one
aryl group, where the aryl group is substituted by at least one alkyl group.
The meanings or preferred meanings given above apply to aryl and alkyl
groups.
For the purposes of the invention, R is selected on each occurrence, identi-
cally or differently, from the group consisting of a straight-chain or
branched
alkyl group having Ito 10 C atoms, a partially halogenated or fully halogen-
ated straight-chain or branched alkyl group having Ito 10 C atoms, a
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 14 -
straight-chain or branched alkoxy group having Ito 10 C atoms or a par-
tially halogenated or fully halogenated straight-chain or branched alkoxy
group having Ito 10 C atoms. R is preferably on each occurrence methyl,
ethyl, trifluoromethyl or methoxy.
For the purposes of the invention, R is a straight-chain or branched alkyl
group having Ito 10 C atoms, preferably a straight-chain or branched alkyl
group having 1 to 4 C atoms.
In an embodiment of the invention, compounds of the formula (1) in which Y
has the meaning 0 and X has the meaning 0, S or NR , where R has a
meaning indicated above, are preferably selected for the composition
according to the invention.
Compounds of the formula (1) in which Y has the meaning 0 and X has the
meaning 0 or S, preferably in which Y has the meaning 0 and X has the
meaning 0, are furthermore preferably selected for the composition accord-
ing to the invention. Particularly preferred compounds of the formula (1) of
this type can be represented by the formula (2),
R1 R5 R6
o o
o /
\ R12_ o __ sp-(xi)a
R2 R3 R4 R7
(2)
R1i> R19
R9 Rs ,
where Xi, a, Sp, R1 to R12 have a meaning given above or preferably given
below.
In compounds of the formula (1) or (2), as described above, Xi is preferably
0 and a corresponds to 0 or I. If the spacer Sp has an even number of C
atoms, a is preferably I. If the spacer Sp as an odd number of C atoms, a is
preferably 0.
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
- 15 -
In compounds of the formula (1) or (2), as described above or preferably
described, Sp is preferably an alkanediyl having 6 to 20 C atoms, which
may be substituted by one or more R, particularly preferably an alkanediyl
having 8,9, 10, 11, 12, 13, 14, 15 or 16 C atoms, which may be substituted
by one or more R, very particularly preferably an alkanediyl having 9, 10,
11, 12, 13 or 14 C atoms, which may be substituted by one or more R. The
alkanediyl, as described above, is preferably unsubstituted. The alkanediyl
is very particularly preferably an alkanediyl having 10, 11, 12 or 13 C atoms
or ¨(CH2)11- and ¨(CH2)12-.
In compounds of the formula (1) or (2), as described above or preferably
described, the substituents Ri, R2, R3 and R4 are preferably H, which can
be represented by compounds of formula (3),
R5 R6
o o
o /
\ ________________ 0¨ Sp-(Xi)a R7
R12.>_ / (3)
Ri Ri0
R6 R8 ,
where Xi, a, Sp, R5 to R12 have a meaning given above or a meaning pref-
erably given above or below.
In an embodiment of the invention, compounds of the formula (1), (2) or (3),
as described above or described as preferred, where the substituents R11
and R12 denote H and Ri has a meaning indicated above are preferably
selected for the composition according to the invention,.
The substituent Ri is preferably H or a straight-chain or branched alkyl
group having 1, 2, 3, 4, 5 or 6 C atoms or a phenyl group which is unsubsti-
tuted or mono- or polysubstituted by R. The substituent Rio in compounds
of the formula (1), (2) or (3) is particularly preferably H, methyl, ethyl or
phenyl, very particularly preferably H or methyl.
If the substituent Rio in compounds of the formula (1), (2) or (3), as
described above, is H, these monomers are then referred to as acrylates.
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
- 16 -
If the substituent Rio in compounds of the formula (1), (2) or (3), as
described above, is methyl, these monomers are then referred to as meth-
acrylates. Acrylates are particularly preferred.
In compounds of the formula (1), (2) and (3), as described above or
described as preferred, the substituents Rii, R12, R6; R6 rc and - "8
are prefera-
bly H, which can be represented by compounds of the formula (4),
_____________ o sp4x0a ___________________________ R7
(4)
R19
R9
where Xi, a, Sp, R7, R9 and R12 have a meaning given above or a meaning
preferably given above or below.
In compounds of the formula (1), (2), (3) or (4), R9 is preferably an unfluori-
nated, partially fluorinated or fully fluorinated straight-chain or branched
alkyl or alkoxy group having 1 to 6 C atoms, where Sp, Xi, a, R7 and R19 or
one of the other substituents R1 to R12 if they appear have a meaning given
above or preferred meaning.
In compounds of the formula (1), (2), (3) or (4), R9 is particularly
preferably
an unfluorinated, partially fluorinated or fully fluorinated straight-chain or
branched alkyl or alkoxy group having 1 to 4 C atoms, where Sp, Xi, a, R7
and Rio or one of the other substituents R1 to R12 if they appear have a
meaning given above or preferred meaning.
In compounds of the formula (1), (2), (3) or (4), R7 is preferably an unfluori-
nated, partially fluorinated or fully fluorinated straight-chain or branched
alkyl group having 2 to 8 C atoms, where Sp, Xi, a, R9 and Rio or one of
the other substituents R1 to R12 if they appear have a meaning given above
or preferred meaning.
In compounds of the formula (1), (2), (3) or (4), R7 is particularly
preferably
an unfluorinated, partially fluorinated or fully fluorinated straight-chain or
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
- 17 -
branched alkyl group having 3 to 8 C atoms, where Sp, Xi, a, R9 and R19 or
one of the other substituents R1 to R12 if they appear have a meaning given
above or preferred meaning.
Preferred examples of the compounds of the formula (1) to (4) which are
selected in accordance with the invention for the composition correspond to
the compounds (M-1) to (M-63):
o o
H2
1 0
0 (M-1)
cH3
cH3
o o
(M-2)
cH3
(M-3)
cH3
cH2
o o
H3c 3
(M-4)
cH3
,
H2c, (M-5)
cH3
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
- 18
o
H2 0 0 CH, (M-6)
CH3
0
H2Cy-
0 0
CH3 0 0
\
(M-7)
cH3
0
(M-8)
0 ,CH3
1-12C)Lo 0 0 0
H3c' (M-9)
cH3
0 CH,
CH3 20 (M-10)
cH3
o o o o
(M-11)
cH3
o
o (M-12)
0 0
o
(M-13)
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
- 19 -
0 0 0 0
-,..õ--
0 / (M-14)
sCI-13
0 0
0 / OCH3 (M-15)
o 0 o
H2C<7.õ,0,_ ,--
-12
0 / (M-16)
H3C
CH3
HC,.._______.-00,0 H,C
2
io 1
0 / / CH, (M-17)
I
H2c--ro
0
F (M-18)
F
F
0 0
C)----------
H2C
0
F F (M-19)
F
F
F
H 2C -----'--------- 12
11
0 / (M-20)
I
,--
F3co C H3
H2C____--000
12
(M-21)
I
H3c
cH3
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 20 -
o o o
o
(M-22)
H3C,0 CH,
H,C
o o
H2Gnr 12
0
(M-23)
CH3
H2C 8 0 0
0
(M-24)
CH,
H 0 0
12
2 0 (M-25)
H3C CH3
o o
0
(M-26)
H3c CH3
CH3 CH3
0 0 0
0
(M-27)
H3c cH3
CH3 CH3
0 0 0
CH3 2C0 12
0 (M-28)
cH3
H3c
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 21 -
o o CH3
12
0 / (M-29)
H3c
0 o CH3
o
(M-30)
0 12 0
H3C
CH3
H2C
_ jirCi,,,.,_____,--00,0 cH
11
1
0 (M-31)
--,
I
H3C CH3
0 0
-----_-/ o
H20n.''' 12 F
/ F
(M-32)
0
F F
F
H2Cir(p1 I
1 1 1
0 / ../ (M-33)
I
F3co CH3
H2c-tio
8
0 ,-
H3c (M-34)
H3c
H3c
-=vo_---'o .. o o
H2C CH,
12
0 /
--, (M-35)
I
H3c CH,
0 --_________--0 ,._'-=_, .S,0
I-I,Cy ii ,
I
0 / / (M-36)
cH3
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 22 -
0
S 0
H,C CH,
(M-37)
CH,
0 0 H2C S S
1-1
0
(M-38)
CH,
0 S
I-120 12
0 (M-39)
H3c cH3
o
H2C 12
0 (M-40)
H,C
CH,
oH,
o 0 S 0
H2C-r
0 (M-41)
F F
o (M-42)
F-/-0
12 0 0
0 (M-43)
FN
0 0 0
0 (M-44)
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
-23 -
o 0 o
o
¨ _12
(M-45)
F
o o
(M-46)
o
0-4'F
0 0
----Tr- 12
0
(M-47)
F F
0 0 0
0
(M-48)
F F
0 ,0
0
F F (M-49)
o 0
0
F F (M-50)
0 0
- 12
0 (M-51)
0 S 0
12
(M-52)
FL
I
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
- 24
o (M-53)
S 0
12
o
(M-54)
0 0
0 10 (M-55)
FO
0 0
O (M-56)
FO
0 0
F
O (M-57)
F
OO
13o
I
F F I (M-58)
ojo0 0
14
0 (M-59)
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
- 25 -
- 12
0 /
FF
(M-60)
F
12 1
0 / / (M-61)
I
0 .,..,,,,,, (M-62)
I
---------:-12 s o
o (M-63).
Besides one or more compounds of the formula (1), (2), (3), (4), as
described above or preferably described or the compounds (M-1) to (M-63),
the composition according to the invention also comprises at least one
hydrophilic monomer in the molar ratio as described above or preferably
described below.
The hydrophilic monomer, as defined above, is, for example, characterised
in that its corresponding homopolymer is soluble in water or swellable in
water. It is distinguished by the presence of polar groups which are able to
coordinate water, for example and preferably OH or NH2 groups.
Suitable examples of hydrophilic monomers are 3-hydroxypropyl meth-
acrylate, 3-hydroxypropyl acrylate, 2-hydroxyethyl methacrylate, 2-hydroxy-
ethyl acrylate, 4-hydroxybutyl methacrylate, 4-hydroxybutyl acrylate, glyc-
eryl methacrylate, glyceryl acrylate, acrylamide, N-vinylpyrrolidone, 6-
hydroxyhexyl methacrylate, 6-hydroxyhexyl acrylate, 18-hydroxyoctadecyl
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 26 -
methacrylate, 18-hydroxyoctadecyl acrylate, 11-hydroxyundecyl meth-
acrylate, 11-hydroxyundecyl acrylate, 12-hydroxydodecyl methacrylate or
12-hydroxydodecyl acrylate or a combination of these compounds.
The hydrophilic monomer for the hydrophilic monomers are preferably
selected from acrylate or methacrylate monomers from the above-
mentioned group.
Preferred hydrophilic monomers are n-hydroxyalkyl acrylates and n-
hydroxyalkyl methacrylates having 1 to 4 C atoms in der alkyl chain.
2-Hydroxyethyl methacrylate (HEMA), 2-hydroxyethyl acrylate (HEA) or a
mixture of these monomers are particularly preferably selected for the com-
position according to the invention.
The invention accordingly furthermore relates to a composition, as
described above or preferably described below, in which the at least one
hydrophilic monomer is selected from 3-hyroxypropyl methacrylate, 3-
hydroxypropyl acrylate, 2-hydroxyethyl methacrylate, 2-hydroxyethyl acry-
late, 4-hydroxybutyl methacrylate, 4-hydroxybutyl acrylate, glyceryl meth-
acrylate, glyceryl acrylate, acrylamide, N-vinylpyrrolidone, 6-hydroxyhexyl
methacrylate, 6-hydroxyhexyl acrylate, 18-hydroxyoctadecyl methacrylate,
18-hydroxyoctadecyl acrylate, 11-hydroxyundecyl methacrylate, 11-
hydroxyundecyl acrylate, 12-hydroxydodecyl methacrylate, 12-hydroxy-
dodecyl acrylate, ethylene glycol phenyl ether acrylate, ethylene glycol
phenyl ether methacrylate or a combination of these compounds.
Besides one or more compounds of the formula (1), (2), (3), (4), as
described above or preferably described or the compounds (M-1) to (M-63),
the composition according to the invention also comprises a hydrophilic
monomer or a combination of hydrophilic monomers, as described above,
where the molar ratio of the sum of all compounds of the formula (1) or the
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
- 27 -
preferred compounds of the formula (1) to the sum of all hydrophilic mono-
mers is preferably 1:0.56 to 1:1.2 or particularly preferably 1:0.6 to 1:1.
Besides one or more compounds of the formula (1), (2), (3), (4), as
described above or preferably described or the compounds (M-1) to (M-63)
and the hydrophilic monomers, as described above, in the said molar ratios,
the composition according to the invention may comprise at least one fur-
ther non-hydrophilic monomer which does not conform to the formula (1)
and/or at least one blue absorber.
The invention therefore furthermore relates to the composition, as
described above or preferably described, characterised in that it comprises
at least one further non-hydrophilic monomer which does not conform to the
formula (1) or a preferred embodiment of the compounds of formula (1).
The invention therefore furthermore relates to the composition, as
described above or preferably described, characterised in that it comprises
at least one blue absorber.
Suitable blue absorbers are substances which exhibit absorption in the blue
wavelength region of visible light. A blue absorber which is likewise an acry-
late or a methacrylate and is available as further monomer during the
polymerisation is preferably selected. Suitable blue absorbers are known
from the literature, for example from WO 2012/167124. A particularly pre-
ferred blue absorber is N-243-(2'-methylphenylazo)-4-hydroxyphenylethy1]-
ethylmethacrylamide. They can be added to the composition according to
the invention in order that the polymerised composition is also able to filter
short-wave visible light in addition to the UV light in order thus to protect
the
retina better if the material is used for the production of an
ophthalmological
product.
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 28 -
The non-hydrophilic monomer or the non-hydrophilic monomers which
do(es) not conform to the formula (1) or a preferred embodiment of the
compounds of the formula (1) can be added for further optimisation of the
composition and the corresponding resultant copolymer. This is a polymer-
isable substance which carries further unsubstituted or substituted aliphatic
radicals and/or unsubstituted or substituted aromatic radicals and/or sulfide
bonds and/or fluorinated radicals. If a substituted aliphatic or aromatic radi-
cal is selected, these are preferably substituted by at least one substituent
R#, where R# on each occurrence, independently of one another, denotes
F, Cl, Br, I, a straight-chain or branched alkyl group having Ito 20 C atoms,
a straight-chain or branched alkoxy group having 1 to 20 C atoms, a par-
tially or fully halogenated straight-chain or branched alkyl group having 1 to
C atoms, a partially or fully halogenated straight-chain or branched
alkoxy group having 1 to 20 C atoms, a cycloalkyl group having 5 to 8 C
15 atoms, an arylalkoxy group having 7 to 20 C atoms or an aryl or
heteroaryl
group having 5 to 40 ring atoms, where the aryl or heteroaryl group or the
aryl group as part of the arylalkkoxy group may be substituted by a straight-
chain or branched alkyl group having 1 to 12 C atoms or a cycloalkyl group
having 5 to 8 C atoms.
Examples of non-hydrophilic monomers are: n-butyl acrylate, n-butyl meth-
acrylate, ethyl methacrylate, ethyl acrylate, methyl methacrylate, methyl
acrylate, n-propyl methacrylate, n-propyl acrylate, isopropyl methacrylate,
isopropyl acrylate, n-pentyl acrylate, n-pentyl methacrylate, isopentyl meth-
acrylate, isopentyl acrylate, s-butyl acrylate, s-butyl methacrylate, n-hexyl
acrylate, n-hexyl methacrylate, s-pentyl acrylate, s-pentyl methacrylate, iso-
hexyl acrylate, isohexyl methacrylate, n-octyl acrylate, n-octyl methacrylate,
isooctyl acrylate, isooctyl methacrylate, n-nonyl acrylate, n-nonyl methacry-
late, n-decyl acrylate, n-decyl methacrylate, n-undecyl acrylate, n-undecyl
methacrylate, n-dodecyll acrylate, n-dodecyl methacrylate, n-octadecyl
acrylate, n-octadecyl methacrylate, 2-ethylhexyl acrylate, 2-ethylhexyl
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 29 -
methacrylate, n-dodecyl acrylate, n-dodecyl methacrylate, n-tridecyl acry-
late, n- tridecyl methacrylate, n-tetradecyl acrylate, n-tetradecyl methacry-
late, n-pentadecyl acrylate, n-pentadecyl methacrylate, n-hexadecyl acry-
late, n-hexadecyl methacrylate, 2,2-dimethylpropyl acrylate, 2,2-dimethyl-
propyl methacrylate, trimethylcyclohexyl acrylate, trimethylcyclohexyl
methacrylate, isobutyl acrylate, isobutyl methacrylate, 2-(4-bromopheny1)-
ethyl methacrylate, 4-phenyl butyl methacrylate, 4-methyl phenyl meth-
acrylate, phenyl methacrylate, 4-methylphenyl acrylate, benzyl acrylate,
benzyl methacrylate, 2-benzyloxyethyl methacrylate, 3-benzyloxypropyl
methacrylate, phenylethyl acrylate, phenylethyl methacrylate, 3-phenyl-
propyl methacrylate, 2-phenoxyethyl acrylate, 2-benzyloxyethyl acrylate, 3-
phenylpropyl acrylate, 4-methylbenzyl acrylate, phenyl acrylate, 2-(phenyl-
thio)ethyl methacrylate, 4-phenyl butyl acrylate, 5-phenylpentyl acrylate, 3-
benzyloxypropyl acrylate, 2-(phenylthio)propyl acrylate, 2-(phenylthio)ethyl
acrylate, 4-phenyl butyl acrylate, 4-methyl benzyl methacrylate, 2-(2-methyl-
phenyl)ethyl acrylate, 2-(2-methylphenyOethyl methacrylate, 2-(3-methyl-
phenyl )ethyl acrylate, 2-(3-methylphenyl)ethyl methacrylate, 2-(4-methyl-
phenyl )ethyl acrylate, 2-(4-methylphenyl)ethyl methacrylate, 2-(4-propyl-
phenyl)ethyl acrylate, 2-(4-propylphenyl)ethyl methacrylate, 2-(4-(1-methyl-
ethyl)phenyl)ethyl acrylate, 2-(4-(1-methylethyl)phenyl)ethyl methacrylate,
2-(4-methoxyphenyl)ethyl methacrylate, 2-(4-methoxyphenyl)ethyl acrylate,
2-(4-cyclohexylphenyl)ethyl acrylate, 2-(4-cyclohexylphenyl)ethyl methacry-
late, 2-(4-chlorophenyl)ethyl methacrylate, 2-(4-chlorophenyl)ethyl acrylate,
2-(3-chlorophenyl)ethyl methacrylate, 2-(3-chlorophenyl)ethyl acrylate, 2-(2-
chlorophenyl)ethyl methacrylate, 2-(2-chlorophenyl)ethyl acrylate, 2-(4-
bromophenyl)ethyl acrylate, 2-(4-phenylphenyl)ethyl methacrylate, 2-(4-
phenylphenyl)ethyl acrylate, 2-(3-phenylphenyl)ethyl methacrylate, 2-(3-
phenylphenyl)ethyl acrylate, 2-(4-benzylphenyl)ethyl methacrylate, 2-(4-
benzylphenyl)ethyl acrylate, 2-(phenylthio)ethyl acrylate, 3-benzyloxypropyl
acrylate, 2-[2-(benzyloxy)ethoxy]ethyl acrylate, 2-[2-(benzyloxy)ethoxy]ethyl
methacrylate, pentafluorophenyl methacrylate, heptadecafluorodecyl meth-
acrylate, dodecafluoroheptyl methacrylate, heptadecafluorodecyl acrylate,
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 30 -
trifluoroethyl methacrylate, octafluoropentyl methacrylate, hexafluorobutyl
methacrylate, octafluoropentyl acrylate, trifluoroethyl acrylate, heptafluoro-
butyl acrylate, tetrafluoropropyl methacrylate, hexafluorobutyl acrylate,
pentafluorophenyl acrylate, hexafluoroisopropyl methacrylate.
Preferred non-hydrophilic monomers are phenoxyalkyl acrylates, phenoxy-
alkyl methacrylates, alkyl acrylates and alkyl methacrylates having a chain
length of 8 to 20 C atoms, and phenylalkoxy acrylates, phenylalkoxy meth-
acrylates, phenylalkoxyalkyl acrylates and phenylalkoxyalkyl methacrylates
having a chain length of the alkylene or alkyloxy group Ito 8 C atoms,
which are preferably straight-chain.
n-Octadecyl methacrylate (C18MA) or 2-phenoxyethyl acrylate (EGPEA) or
a combination of these compounds is particularly preferably selected as
non-hydrophilic monomer. A synonymous name for 2-phenylethyl acrylate
is ethylene glycol phenyl ether acrylate.
The invention furthermore relates to a composition, as described above or
described as preferred, in which at least one non-hydrophilic monomer is
selected from n-butyl acrylate, n-butyl methacrylate, ethyl methacrylate,
ethyl acrylate, methyl methacrylate, methyl acrylate, n-propyl methacrylate,
n-propyl acrylate, isopropyl methacrylate, isopropyl acrylate, n-pentyl acry-
late, n-pentyl methacrylate, isopentyl methacrylate, isopentyl acrylate,
s-butyl acrylate, s-butyl methacrylate, n-hexyl acrylate, n-hexyl methacry-
late, s-pentyl acrylate, s-pentyl methacrylate, isohexyl acrylate, isohexyl
methacrylate, n-octyl acrylate, n-octyl methacrylate, isooctyl acrylate, iso-
octyl methacrylate, n-nonyl acrylate, n-nonyl methacrylate, n-decyl acrylate,
n-decyl methacrylate, n-undecyl acrylate, n-undecyl methacrylate, n-
dodecyll acrylate, n-dodecyl methacrylate, n-octadecyl acrylate, n-octadecyl
methacrylate, 2-ethylhexyl acrylate, 2-ethylhexyl methacrylate, n-dodecyl
acrylate, n-dodecyl methacrylate, n-tridecyl acrylate, n-tridecyl methacry-
late, n-tetradecyl acrylate, n-tetradecyl methacrylate, n-pentadecyl acrylate,
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 31 -
n-pentadecyl methacrylate, n-hexadecyl acrylate, n-hexadecyl methacry-
late, 2,2-dimethylpropyl acrylate, 2,2-dimethylpropyl methacrylate, trimethyl-
cyclohexyl acrylate, trimethylcyclohexyl methacrylate, isobutyl acrylate, iso-
butyl methacrylate, 2-(4-bromophenyl)ethyl methacrylate, 4-phenyl butyl
methacrylate, 4-methylphenyl methacrylate, phenyl methacrylate, 4-methyl-
phenyl acrylate, benzyl acrylate, benzyl methacrylate, 2-benzyloxyethyl
methacrylate, 3-benzyloxypropyl methacrylate, phenylethyl acrylate,
phenylethyl methacrylate, 3-phenylpropyl methacrylate, 2-phenoxyethyl
acrylate, 2-benzyloxyethyl acrylate, 3-phenylpropyl acrylate, 4-methylbenzyl
acrylate, phenyl acrylate, 2-(phenylthio)ethyl methacrylate, 4-phenylbutyl
acrylate, 5-phenylpentyl acrylate, 3-benzyloxypropyl acrylate, 2-(phenyl-
thio)propyl acrylate, 2-(phenylthio)ethyl acrylate, 4-phenylbutyl acrylate, 4-
methyl benzyl methacrylate, 2-(2-methylphenyl)ethyl acrylate, 2-(2-methyl-
phenyl )ethyl methacrylate, 2-(3-methylphenyl)ethyl acrylate, 2-(3-methyl-
phenyl )ethyl methacrylate, 2-(4-methylphenyl)ethyl acrylate, 2-(4-methyl-
phenyl)ethyl methacrylate, 2-(4-propylphenyl)ethyl acrylate, 2-(4-propyl-
phenyl)ethyl methacrylate, 2-(4-(1-methylethyl)phenyl)ethyl acrylate, 2-(4-
(1-methylethyl)phenyl)ethyl methacrylate, 2-(4-methoxyphenyl)ethyl meth-
acrylate, 2-(4-methoxyphenyl)ethyl acrylate, 2-(4-cyclohexylphenyl)ethyl
acrylate, 2-(4-cyclohexylphenyl)ethyl methacrylate, 2-(4-chlorophenyl)ethyl
methacrylate, 2-(4-chlorophenyl)ethyl acrylate, 2-(3-chlorophenyl)ethyl
methacrylate, 2-(3-chlorophenyl)ethyl acrylate, 2-(2-chlorophenyl)ethyl
methacrylate, 2-(2-chlorophenyl)ethyl acrylate, 2-(4-bromophenyl)ethyl
acrylate, 2-(4-phenylphenyl)ethyl methacrylate, 2-(4-phenylphenyl)ethyl
acrylate, 2-(3-phenylphenyl)ethyl methacrylate, 2-(3-phenylphenyl)ethyl
acrylate, 2-(4-benzylphenyl)ethyl methacrylate, 2-(4-benzylphenyl)ethyl
acrylate, 2-(phenylthio)ethyl acrylate, 3-benzyloxypropyl acrylate, 242-
(benzyloxy)ethoxy]ethyl acrylate, 2-[2-(benzyloxy)ethoxy]ethyl methacry-
late, pentafluorophenyl methacrylate, heptadecafluorodecyl methacrylate,
dodecafluoroheptyl methacrylate, heptadecafluorodecyl acrylate, trifluoro-
ethyl methacrylate, octafluoropentyl methacrylate, hexafluorobutyl meth-
acrylate, octafluoropentyl acrylate, trifluoroethyl acrylate, heptafluorobutyl
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 32 -
acrylate, tetrafluoropropyl methacrylate, hexafluorobutyl acrylate, penta-
fluorophenyl acrylates, hexafluoroisopropyl methacrylate or a combination
of these compounds.
The compositions according to the invention, as described above, also
comprise at least one crosslinker and at least one UV absorber. It is also
possible here for one substance to take on both properties, i.e. to be cross-
linker and UV absorber the same time.
A crosslinker is a monomer containing at least two polymerisable groups.
The crosslinker preferably has two polymerisable groups. The crosslinker
may optionally also contain functional groups which are capable of coordi-
nating water, such as, for example, OH or NH2 groups. Crosslinkers func-
tionalised in this way are likewise suitable hydrophilic monomers in the
sense of the invention and are preferably employed in combination with the
hydrophilic monomers described above.
Examples of crosslinkers are:
para-divinylbenzene, allyl acrylate, ethylene glycol divinyl ether, divinyl
sul-
fone, ally! methacrylate, N,N'-methylene-bis-acrylamide, ethylene glycol
diacrylate, N,N'-methylene-bis-methacrylamide, 1,3-propanediol diacrylate,
2,3-propanediol diacrylate, 1,4-butanediol diacrylate, 1,3-butanediol diacry-
late, 1,5-pentanediol diacrylate, 1,6-hexanediol diacrylate, 1,7-heptanediol
diacrylate, 1,8-octanediol diacrylate, 1,9-nonanediol diacrylate, 1,10-
decanediol diacrylate, 1,11-undecanediol diacrylate, 1,12-dodecanediol
diacrylate, 1,13-tridecanediol diacrylate, 1,14-tetradecanediol diacrylate,
1,15-pentadecanediol diacrylate, 1,16-hexadecanediol diacrylate, 1,17-
heptadecanediol diacrylate, 1,18-octadecanediol diacrylate, 1,19-nona-
decanediol diacrylate, 1,20-eicosanediol diacrylate, 1,21-heneicosanediol
diacrylate, 1,22-docosanediol diacrylate, 1,23-tricosanediol diacrylate, 1,24-
tetracosanediol diacrylate, ethylene glycol dimethacrylate, N,N'-dihydroxy-
ethylenebisacrylamide, thiodiethylene glycol diacrylate, 1,3-propanediol
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
- 33 -
dimethacrylate, 2,3-propanediol dimethacrylate, 1,3-butanediol dimethacry-
late, 1,4-butanediol dimethacrylate, 1,5-pentanediol dimethacrylate, 1,6-
hexanediol dimethacrylate, 1,7-heptanediol dimethacrylate, 1,8-octanediol
dimethacrylate, 1,9-nonanediol dimethacrylate, 1,10-decanediol dimeth-
acrylate, 1,11-undecanediol dimethacrylate, 1,12-dodecanediol dimethacry-
late, 1,13-tridecanediol dimethacrylate, 1,14-tetradecanediol dimethacry-
late, 1,15-pentadecanediol dimethacrylate, 1,16-hexadecanediol dimeth-
acrylate, 1,17-heptadecanediol dimethacrylate, 1,18-octadecanediol
dimethacrylate, 1,19-nonadecanediol dimethacrylate, 1,20-eicosanediol
dimethacrylate, 1,21-heneicosanediol dimethacrylate, 1,22-docosanediol
dimethacrylate, 1,23-tricosanediol dimethacrylate, 1,24-tetracosanediol
dimethacrylate, 2-(acryloyloxy)ethyl methacrylate, 2-(acryloyloxy)propyl
methacrylate, 3-(acryloyloxy)propyl methacrylate, 4-(acryloyloxy)butyl meth-
acrylate, 5-(acryloyloxy)pentyl methacrylate, 6-(acryloyloxy)hexyl methacry-
late, 7-(acryloyloxy)heptyl methacrylate, 8-(acryloyloxy)octyl methacrylate,
9-(acryloyloxy)nonyl methacrylate, 10-(acryloyloxy)decyl methacrylate, 11-
(acryloyloxy)undecyl methacrylate, 12-(acryloyloxy)dodecyl methacrylate,
13-(acryloyloxy)tridecyl methacrylate, 14-(acryloyloxy)tetradecyl methacry-
late, 15-(acryloyloxy)pentadecyl methacrylate, 16-(acryloyloxy)hexadecyl
methacrylate, 17-(acryloyloxy)heptadecyl methacrylate, 18-(acryloyloxy)-
octadecyl methacrylate, 19-(acryloyloxy)nonadecyl methacrylate, 20-(acryl-
oyloxy)eicosanyl methacrylate, 21-(acryloyloxy)heneicosanyl methacrylate,
22-(acryloyloxy)docosanyl methacrylate, 23-(acryloyloxy)tricosanyl meth-
acrylate, 24-(acryloyloxy)tetracosanyl methacrylate, neopentyl glycol diacry-
late, di(ethylene glycol) diacrylate, N,N'-hexamethylenebisacrylamide, thio-
diethylene glycol diacrylate, thiodiethylene glycol dimethacrylate, neopentyl
glycol dimethacrylate, diethylene glycol dimethacrylate, diallyl phthalate,
tri-
ally! cyanurate, glyceryl 1,3-dimethacrylate, N,N'-hexamethylenebismeth-
acrylamide, tri(ethylene glycol) diacrylate, tri(ethylene glycol) dimethacry-
late, tetra(ethylene glycol) diacrylate, tetra(ethylene glycol)
dimethacrylate,
penta(ethylene glycol) diacrylate, penta(ethylene glycol) dimethacrylate,
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
- 34 -
hexa(ethylene glycol) diacrylate, hexa(ethylene glycol) dimethacrylate,
poly(ethylene glycol) dimethacrylate, poly(ethylene glycol) diacrylate.
Preferred crosslinkers are ethylene glycol dimethacrylate, 1,3-propanediol
diacrylate, 2,3-propanediol diacrylate, 1,4-butanediol diacrylate, 1,3-butane-
diol diacrylate, 1,5-pentanediol diacrylate, 1,6-hexanediol diacrylate, 1,7-
heptanediol diacrylate, 1,8-octanediol diacrylate, 1,9-nonanediol diacrylate,
1,10-decanediol diacrylate, 1,11-undecanediol diacrylate, 1,12-dodecane-
diol diacrylate, 1,13-tridecanediol diacrylate, 1,14-tetradecanediol diacry-
late, 1,15-pentadecanediol diacrylate, 1,16-hexadecanediol diacrylate,
1,17-heptadecanediol diacrylate, 1,18-octadecanediol diacrylate, 1,19-
nonadecanediol diacrylate, 1,20-eicosanediol diacrylate, 1,21-heneicosane-
diol diacrylate, 1,22-docosanediol diacrylate, 1,23-tricosanediol diacrylate,
1,24-tetracosanediol diacrylate, 1,3-propanediol dimethacrylate, 2,3-pro-
panediol dimethacrylate, 1,3-butanediol dimethacrylate, 1,4-butanediol
dimethacrylate, 1,5-pentanediol dimethacrylate, 1,6-hexanediol dimethacry-
late, 1,7-heptanediol dimethacrylate, 1,8-octanediol dimethacrylate, 1,9-
nonanediol dimethacrylate, 1,10-decanediol dimethacrylate, 1,11-
undecanediol dimethacrylate, 1,12-dodecanediol dimethacrylate, 1,13-tri-
decanediol dimethacrylate, 1,14-tetradecanediol dimethacrylate, 1,15-
pentadecanediol dimethacrylate, 1,16-hexadecanediol dimethacrylate,
1,17-heptadecanediol dimethacrylate, 1,18-octadecanediol dimethacrylate,
1,19-nonadecanediol dimethacrylate, 1,20-eicosanediol dimethacrylate,
1,21-heneicosanediol dimethacrylate, 1,22-docosanediol dimethacrylate,
1,23-tricosanediol dimethacrylate, 1,24-tetracosanediol dimethacrylate,
glyceryl 1,3-dimethacrylate and diallyl phthalate.
Glyceryl 1,3- dimethacrylate (GDMA), ethylene glycol dimethacrylate
(EGDMA), penta(ethylene glycol) dimethacrylate, hexa(ethylene glycol)
dimethacrylate or a combination of these compounds is very particularly
preferably selected in accordance with the invention.
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 35 -
Particularly preferred crosslinkers are ethylene glycol dimethacrylate, 1,3-
propanediol diacrylate, 1,4-butanediol dimethacrylate, 1,6-hexanediol
dimethacrylate, 1,18-octadecanediol diacrylate, 1,18-octadecanediol
dimethacrylate, glyceryl 1,3-dimethacrylate and diallyl phthalate. Glyceryl
1,3-dimethacrylate (GDMA), ethylene glycol dimethacrylate (EGDMA),
penta(ethylene glycol) dimethacrylate, hexa(ethylene glycol) dimethacry-
late, 1,18-octadecanediol diacrylate, 1,18-octadecanediol dimethacrylate,
18-(acryloyloxy)octadecyl methacrylate, 1-acryloy1-18-octadecanediol
dimethacrylate or a combination of these compounds is very particularly
preferably selected in accordance with the invention.
The invention accordingly furthermore relates to a composition, as
described above or preferably described below, in which the crosslinker is
selected from the group para-divinylbenzene, allyl acrylate, ethylene glycol
divinyl ether, divinyl sulfone, allyl methacrylate, N,N'-methylene-bis-acryl-
amide, ethylene glycol diacrylate, N,N'-methylene-bis-methacrylamide, 1,3-
propanediol diacrylate, 2,3-propanediol diacrylate, 1,4-butanediol diacry-
late, 1,3-butanediol diacrylate, 1,5-pentanediol diacrylate, 1,6-hexanediol
diacrylate, 1,7-heptanediol diacrylate, 1,8-octanediol diacrylate, 1,9-nona-
nediol diacrylate, 1,10-decanediol diacrylate, 1,11-undecanediol diacrylate,
1,12-dodecanediol diacrylate, 1,13-tridecanediol diacrylate, 1,14-tetra-
decanediol diacrylate, 1,15-pentadecanediol diacrylate, 1,16-hexadecane-
diol diacrylate, 1,17-heptadecanediol diacrylate, 1,18-octadecanediol
diacrylate, 1,19-nonadecanediol diacrylate, 1,20-eicosanediol diacrylate,
1,21-heneicosanediol diacrylate, 1,22-docosanediol diacrylate, 1,23-tri-
cosanediol diacrylate, 1,24-tetracosanediol diacrylate, ethylene glycol
dimethacrylate, N,N'-dihydroxyethylenebisacrylamide, thiodiethylene glycol
diacrylate, 1,3-propanediol dimethacrylate, 2,3-propanediol dimethacrylate,
1,3-butanediol dimethacrylate, 1,4-butanediol dimethacrylate, 1,5-pentane-
diol dimethacrylate, 1,6-hexanediol dimethacrylate, 1,7-heptanediol dimeth-
acrylate, 1,8-octanediol dimethacrylate, 1,9-nonanediol dimethacrylate,
1,10-decanediol dimethacrylate, 1,11-undecanediol dimethacrylate, 1,12-
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
- 36 -
dodecanediol dimethacrylate, 1,13-tridecanediol dimethacrylate, 1,14-tetra-
decanediol dimethacrylate, 1,15-pentadecanediol dimethacrylate, 1,16-
hexadecanediol dimethacrylate, 1,17-heptadecanediol dimethacrylate,
1,18-octadecanediol dimethacrylate, 1,19-nonadecanediol dimethacrylate,
1,20-eicosanediol dimethacrylate, 1,21-heneicosanediol dimethacrylate,
1,22-docosanediol dimethacrylate, 1,23-tricosanediol dimethacrylate, 1,24-
tetracosanediol dimethacrylate, 2-(acryloyloxy)ethyl methacrylate, 2-(acryl-
oyloxy)propyl methacrylate, 3-(acryloyloxy)propyl methacrylate, 4-(acryl-
oyloxy)butyl methacrylate, 5-(acryloyloxy)pentyl methacrylate, 6-(acryl-
oyloxy)hexyl methacrylate, 7-(acryloyloxy)heptyl methacrylate, 8-(acryl-
oyloxy)octyl methacrylate, 9-(acryloyloxy)nonyl methacrylate, 10-(acryl-
oyloxy)decyl methacrylate, 11-(acryloyloxy)undecyl methacrylate, 12-(acryl-
oyloxy)dodecyl methacrylate, 13-(acryloyloxy)tridecyl methacrylate, 14-
(acryloyloxy)tetradecyl methacrylate, 15-(acryloyloxy)pentadecyl methacry-
late, 16-(acryloyloxy)hexadecyl methacrylate, 17-(acryloyloxy)heptadecyl
methacrylate, 18-(acryloyloxy)octadecyl methacrylate, 19-(acryloyloxy)-
nonadecyl methacrylate, 20-(acryloyloxy)eicosanyl methacrylate, 21-(acryl-
oyloxy)heneicosanyl methacrylate, 22-(acryloyloxy)docosanyl methacrylate,
23-(acryloyloxy)tricosanyl methacrylate, 24-(acryloyloxy)tetracosanyl meth-
acrylate, neopentyl glycol diacrylate, di(ethylene glycol) diacrylate, N,N'-
hexamethylenebisacrylamide, thiodiethylene glycol diacrylate, thiodiethy-
lene glycol dimethacrylate, neopentyl glycol dimethacrylate, diethylene gly-
col dimethacrylate, diallyl phthalate, triallyl cyanurate, glyceryl 1,3-
dimeth-
acrylate, N,N'-hexamethylenebismethacrylamide, tri(ethylene glycol) diacry-
late, tri(ethylene glycol) dimethacrylate, tetra(ethylene glycol) diacrylate,
tetra(ethylene glycol) dimethacrylate, penta(ethylene glycol) diacrylate,
penta(ethylene glycol) dimethacrylate, hexa(ethylene glycol) diacrylate,
hexa(ethylene glycol) dimethacrylate, poly(ethylene glycol) dimethacrylate,
poly(ethylene glycol) diacrylate or a combination of these compounds.
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
- 37 -
The UV absorber to be selected in accordance with the invention is a mole-
cule containing a polymerisable group and having strong absorption in the
UV range.
Examples of UV absorbers are:
3-(3-(tert-buty1)-4-hydroxy-5-(5-methoxy-2H-benzo[d]-1,2,3-triazol-2-y1)-
phenoxy)propyl methacrylate, 2-(2-hydroxy-5-vinylphenyI)-2H-benzo-
triazole, allyI-2-hydroxybenzophenone, 2-ally1-6-(2H-benzotriazol-2-y1)-p-
cresol, 4-methacryloxy-2-hydroxybenzophenone, 2-(2'-hydroxy-3'-methallyl-
5'-methylphenyl)benzotriazole, 2-hydroxy-4-methacryloyloxybenzophenone,
4-acryloylethoxy-2-hydroxybenzophenone, 243-(2H-benzotriazol-2-y1)-4-
hydroxyphenyl]ethyl methacrylate, 2-(2'-hydroxy-5'-methacrylamidophenyI)-
5-methoxybenzotriazole, 2-(2'-hydroxy-5'-methacrylamidophenyI)-5-chloro-
benzotriazole, 2-(2'-hydroxy-5'-methacryloxypropylphenyl)benzotriazole, 2-
(2'-hydroxy-5'-methacryloylpropy1-3'-tert-butyl-pheny1)-5-methoxy-2H-
benzotriazol, 2-(3-(tert-buty1)-4-hydroxy-5-(5-methoxy-2H-benzo[d]-1,2,3-
triazol-2-yl)phenoxy)ethyl methacrylate, 243'-tert-buty1-2'-hydroxy-5'-(3"-
methacryloyloxypropyl)pheny1]-5-chlorobenzotriazole, 2-{2'-hydroxy-3'-tert-
buty1-5'43'-methacryloyloxypropoxy]pheny1}-5-methoxy-2H-benzotriazole, 2-
[31tert-buty1-5'-(3"-dimethylvinylsilylpropoxy)-2'-hydroxyphenyl]-5-methoxy-
benzotriazole, 2-(tert-buty1)-6-(5-chloro-2H-benzo[d]-1,2,3-triazol-2-y1)-4-
vinylphenol, 2-(2H-1,2,3-benzotriazol-2-y1)-4-methy1-6-(2-methylprop-2-
enyl)phenol, 2-(3-acetyl-2-aminophenoxy)ethyl methacrylate, 2-(4-benzoy1-
3-hydroxyphenoxy)ethyl acrylate.
Preferred UV absorbers are methacrylates and acrylates of phenyltriazoles
or benzotriazoles, preferably of benzotriazoles.
A particularly preferred UV absorber is 243-(2H-benzotriazol-2-y1)-4-
hydroxyphenyl]ethyl methacrylate or 3-(3-(tert-buty1)-4-hydroxy-5-(5-
methoxy-2H-benzo[d]-1,2,3-triazol-2-yl)phenoxy)propyl methacrylate.
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 38 -
The invention accordingly furthermore relates to a composition, as
described above or preferably described below, in which the UV absorber is
selected from the group 3-(3-(tert-buty1)-4-hydroxy-5-(5-methoxy-2H-benzo-
[d]-1,2,3-triazol-2-yl)phenoxy)propyl methacrylate, 2-(2-hydroxy-5-vinyl-
phenyl)-2H-benzotriazole, allyI-2-hydroxybenzophenone, 2-ally1-6-(2H-
benzotriazol-2-y1)-p-cresol, 4-methacryloxy-2-hydroxybenzophenone, 2-(2'-
hydroxy-3'-methally1-5'-methylphenyl)benzotriazole, 2-hydroxy-4-methacryl-
oyloxybenzophenone, 4-acryloylethoxy-2-hydroxybenzophenone, 243-(2H-
benzotriazol-2-y1)-4-hydroxyphenyl]ethyl methacrylate, 2-(2'-hydroxy-5'-
methacrylamidophenyI)-5-methoxybenzotriazole, 2-(2'-hydroxy-5'-meth-
acrylamidopheny1)-5-chlorobenzotriazole, 2-(2'-hydroxy-5'-methacryloxy-
propylphenyl)benzotriazole, 2-(2'-hydroxy-5'-methacryloylpropy1-3'-tert-
butyl-pheny1)-5-methoxy-2H-benzotriazole, 2-(3-(tert-buty1)-4-hydroxy-5-(5-
methoxy-2H-benzo[d]-1,2,3-triazol-2-yl)phenoxy)ethyl methacrylate, 243'-
tert-buty1-2'-hydroxy-5'-(3"-methacryloyloxypropyl)pheny1]-5-chlorobenzo-
triazole, 2-{2'-hydroxy-3'-tert-buty1-5'43'-methacryloyloxypropoxylpheny1}-5-
methoxy-2H-benzotriazole, 2431tert-buty1-5'-(3"-dimethylvinylsilylpropoxy)-
2'-hydroxypheny1]-5-methoxybenzotriazole, 2-(tert-buty1)-6-(5-chloro-2H-
benzo[d]-1,2,3-triazol-2-y1)-4-vinylphenol, 2-(2H-1,2,3-benzotriazol-2-y1)-4-
methyl-6-(2-methylprop-2-enyl)phenol, 2-(3-acetyl-2-aminophenoxy)ethyl
methacrylate, 2-(4-benzoy1-3-hydroxyphenoxy)ethyl acrylate or a combina-
tion of these compounds.
The invention furthermore relates to a composition, as described above or
preferably described, characterised in that it comprises
1 molar equivalent of a compound of the formula (1) or a preferred com-
pound of the formula (1), as described above, or 1 molar equivalent of the
sum of all compounds of the formula (1), as described above or preferably
described;
0.51 to 1.24 molar equivalents of the hydrophilic monomers, as described
above or preferably described;
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 39 -
0 to 1.0 molar equivalents of the non-hydrophilic monomers which do not
conform to the formula (1), as described above or preferably described;
0.04 to 0.5 molar equivalents of the crosslinker(s), as described above or
preferably described and
0.005 to 0.05 molar equivalents of the UV absorber(s), as described above
or preferably described.
The invention furthermore relates to a composition, as described above or
preferably described, characterised in that it comprises
1 molar equivalent of a compound of the formula (1) or a preferred com-
pound of the formula (1), as described above, or 1 molar equivalent of the
sum of all compounds of the formula (1), as described above or preferably
described;
0.51 to 1.24 molar equivalents of the hydrophilic monomers, as described
above or preferably described;
0 to 0.2 molar equivalents of the non-hydrophilic monomers which do not
conform to the formula (1), as described above or preferably described;
0.05 to 0.5 molar equivalents of the crosslinker(s), as described above or
preferably described and
0.005 to 0.05 molar equivalents of the UV absorber(s), as described above
or preferably described.
The invention furthermore relates to a composition, as described above or
preferably described, characterised in that it comprises
1 molar equivalent of a compound of the formula (1) or a preferred com-
pound of the formula (1), as described above, or 1 molar equivalent of the
sum of all compounds of the formula (1), as described above or preferably
described;
0.51 to 1.24 molar equivalents of the hydrophilic monomers, as described
above or preferably described;
0.05 to 1.0 molar equivalents of the non-hydrophilic monomers which do
not conform to the formula (1), as described above or preferably described;
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
-40 -
0.04 to 0.5 molar equivalents of the crosslinker(s), as described above or
preferably described and
0.005 to 0.05 molar equivalents of the UV absorber(s), as described above
or preferably described.
The invention furthermore relates to a composition, as described above or
preferably described, characterised in that it comprises
1 molar equivalent of a compound of the formula (1) or a preferred com-
pound of the formula (1), as described above, or 1 molar equivalent of the
sum of all compounds of the formula (1), as described above or preferably
described;
0.51 to 1.24 molar equivalents of the hydrophilic monomers, as described
above or preferably described;
0.05 to 0.2 molar equivalents of the non-hydrophilic monomers which do
not conform to the formula (1), as described above or preferably described;
0.05 to 0.5 molar equivalents of the crosslinker(s), as described above or
preferably described and
0.005 to 0.05 molar equivalents of the UV absorber(s), as described above
or preferably described.
In an embodiment of the composition according to the invention, it is pre-
ferred if,
besides the one molar equivalent of a compound of the formula (1), (2), (3),
(4) or a preferred compound, as described above, for example (M-1) to
(M-63), or the sum of all compounds of this type,
it comprises 0.56 to 1.2 molar equivalents or preferably 0.6 to one molar
equivalent of all hydrophilic monomers, as described above or as preferably
described.
In an embodiment of the composition according to the invention, it is pre-
ferred if,
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 41 -
besides the one molar equivalent of a compound of the formula (1), (2), (3),
(4) or a preferred compound, as described above, for example (M-1) to
(M-63), or the sum of all compounds of this type,
it comprises 0.1 to 0.2 molar equivalents of the sum of the non-hydrophilic
monomers, as described above or preferably described.
In an embodiment of the composition according to the invention, it is pre-
ferred if,
besides the one molar equivalent of a compound of the formula (1), (2), (3),
(4) or a preferred compound, as described above, for example (M-1) to
(M-63), or the sum of all compounds of this type,
it comprises 0.01 to 0.03 molar equivalents of the sum of the crosslinkers,
as described above or preferably described.
In an embodiment of the composition according to the invention, it is pre-
ferred if,
besides the one molar equivalent of a compound of the formula (1), (2), (3),
(4) or a preferred compound, as described above, for example (M-1) to
(M-63), or the sum of all compounds of this type,
it comprises 0.05 to 0.3 molar equivalents of the sum of the crosslinkers, as
described above or preferably described.
In an embodiment of the composition according to the invention, it is pre-
ferred if,
besides the one molar equivalent of a compound of the formula (1), (2), (3),
(4) or a preferred compound, as described above, for example (M-1) to
(M-63), or the sum of all compounds of this type,
it comprises 0.007 to 0.02 molar equivalents of the sum of the UV absorb-
ers, as described above or preferably described.
In an embodiment of the composition according to the invention, it is pre-
ferred if,
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
-42 -
besides the one molar equivalent of a compound of the formula (1), (2), (3),
(4) or a preferred compound, as described above, for example (M-1) to
(M-63), or the sum of all compounds of this type and the above-mentioned
molar equivalents of the sum of the hydrophilic monomers, non-hydrophilic
monomers, crosslinkers and UV absorbers,
it comprises 0 to 0,004 molar equivalents of the sum of the blue absorbers,
as described above or preferably described, or preferably 1 micromolar
equivalent to 0.004 molar equivalents of the sum of the blue absorbers, as
described above or preferably described, or particularly preferably 8 micro-
molar equivalents to 0.002 molar equivalents of the sum blue absorbers, as
described above or preferably described.
The suitable choice of the amount of the blue absorber is dependent on the
band position and the corresponding extinction coefficient, so that the per-
son skilled in the art is capable of adapting the above-mentioned molar
equivalents of the blue absorber correspondingly. The choice of the amount
of the blue absorber should be selected so that this influences the UV/VIS
spectrum of the copolymer according to the invention in such a way that the
transmission in the blue wavelength range is minimal.
In the composition according to the invention, as described above or as
preferably described, a free-radical initiator is also added in order that
polymerisation of the monomer composition according to the invention, as
described above, can take place.
The term initiator, free-radical starter or free-radical initiator is used
synony-
mously.
The polarisation is preferably initiated by means of free radicals, both ther-
mal initiators, such as acetyl peroxide, stearoyl peroxide, 2,2'-Azo-bis-(iso-
butyronitrile), tert-butyl peroxypivalate, 2,2`-azo-bis-(2-cyanobutane
nitrile),
benzoyl peroxide, Luperox TBEC, 2,2'-(diazene-1,2-diy1)bis(2,4-dimethyl-
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
-43 -
pentane nitrile), decanoyl peroxide, di(tert-butylcyclohexyl) peroxydicarbon-
ate, lauroyl peroxide, tert-butyl peroxydiethylacetate, tert-butyl peroxy-2-
ethylhexanoate, tert-amyl peroxy-2-ethylhexanoate, VA-086, 1,1'-azo-
di(hexahydrobenzonitrile), 1,1-bis(tert-butylperoxy)-3,3,5-trimethylcyclo-
hexane, peroxy dicarbonate, and also photochemical initiators, such as
Darocur 2273, Darocur 3331, Darocur 1164, lrgacur 1850, Darocur 1700,
Darocur 1173, lrgacur 184, Darocur 1116, Darocur 2959, benzoin methyl
ether, benzoin ethyl ether, lrgacur 651, 2,4,6-(trimethylbenzoyl)diphenyl-
phosphine oxide, bis(2,4,6-trimethylbenzoyl)phenylphosphine oxide,
bis(2,6-dichlorobenzoyI)-4-propylphenylphosphine oxide, are suitable for
this purpose.
A thermal initiator is preferably used. A thermal initiator as described above
is preferably used. 1,1-Bis(tert-butylperoxy)-3,3,5-trimethylcyclohexane,
tert-butyl peroxy-2-ethylhexanoate and tert-amyl peroxy-2-ethylhexanoate
are particularly preferably employed as free-radical initiator, preferably in
0.0025 to 0.05 molar equivalents, based on the sum of all compounds of
the formula (1), as described above or as preferably described, present in
the composition.
The invention therefore furthermore relates to a composition, as described
above, where the composition comprises a free-radical initiator.
The invention furthermore relates to a composition, as described above or
preferably described, characterised in that it comprises
1 molar equivalent of a compound of the formula (1) or a preferred com-
pound of the formula (1), as described above, or 1 molar equivalent of the
sum of all compounds of the formula (1), as described above or preferably
described;
0.51 to 1.24 molar equivalents of the hydrophilic monomers, as described
above or preferably described;
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
-44 -
0 to 0.2 molar equivalents of the non-hydrophilic monomers which do not
conform to the formula (1), as described above or preferably described;
0.05 to 0.5 molar equivalents of the crosslinker(s), as described above or
preferably described;
0.005 to 0.05 molar equivalents of the UV absorber(s), as described above
or preferably described;
0 to 0.004 molar equivalents of the blue absorber(s), as described above or
preferably described;
0.0025 to 0.05 molar equivalents of a free-radical initiator, as described
above or preferably described.
The invention furthermore relates to a composition, as described above or
preferably described, characterised in that it comprises
1 molar equivalent of a compound of the formula (1) or a preferred com-
pound of the formula (1), as described above, or 1 molar equivalent of the
sum of all compounds of the formula (1), as described above or preferably
described;
0.51 to 1.24 molar equivalents of the hydrophilic monomers, as described
above or preferably described;
0 to 1.0 molar equivalents of the non-hydrophilic monomers which do not
conform to the formula (1), as described above or preferably described;
0.04 to 0.5 molar equivalents of the crosslinker(s), as described above or
preferably described;
0.005 to 0.05 molar equivalents of the UV absorber(s), as described above
or preferably described;
0 to 0.004 molar equivalents of the blue absorber(s), as described above or
preferably described;
0.0025 to 0.05 molar equivalents of a free-radical initiator, as described
above or preferably described.
The invention furthermore relates to a composition, as described above or
preferably described, characterised in that it consists of
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
-45 -
one molar equivalent of a compound of the formula (1) or a preferred com-
pound of the formula (1), as described above, or one molar equivalent of
the sum of all compounds of the formula (1), as described above or prefera-
bly described;
0.51 to 1.24 molar equivalents of the hydrophilic monomers, as described
above or preferably described;
0 to 0.2 molar equivalents of the non-hydrophilic monomers which do not
conform to the formula (1), as described above or preferably described;
0.05 to 0.5 molar equivalents of the crosslinker(s), as described above or
preferably described;
0.005 to 0.05 molar equivalents of the UV absorber(s), as described above
or preferably described;
0 to 0.004 molar equivalents of the blue absorber(s), as described above or
preferably described;
0.005 to 0.05 molar equivalents of a free-radical initiator, as described
above or preferably described.
In this embodiment, the molar equivalents of the constituents indicated as
preferred apply correspondingly, as described above.
The invention furthermore relates to a composition, as described above or
preferably described, characterised in that it consists of
one molar equivalent of a compound of the formula (1) or a preferred com-
pound of the formula (1), as described above, or one molar equivalent of
the sum of all compounds of the formula (1), as described above or prefera-
bly described;
0.51 to 1.24 molar equivalents of the hydrophilic monomers, as described
above or preferably described;
0 to 1.0 molar equivalents of the non-hydrophilic monomers, preferably 0 to
0.2 molar equivalents of the non-hydrophilic monomers which do not con-
form to the formula (1), as described above or preferably described;
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
-46 -
0.04 to 0.5 molar equivalents of the crosslinker(s), as described above or
preferably described;
0.005 to 0.05 molar equivalents of the UV absorber(s), as described above
or preferably described;
0 to 0.004 molar equivalents of the blue absorber(s), as described above or
preferably described;
0.0025 to 0.05 molar equivalents of a free-radical initiator, as described
above or preferably described.
For the composition, the embodiments and the preferred embodiments of
the constituents of the composition can be combined as desired. It is pre-
ferred if in each case the preferred embodiments of the respective constitu-
ents and their amounts are combined.
If the composition according to the invention, as described above or as
preferably described, is polymerised, crosslinked copolymers form which
are soft from an ambient temperature between 16 C and 20 C and have all
advantages as described above. They exhibit, in particular, no or virtually
no glistening. The term "no or virtually no glistening" has the meaning as
described above. The copolymers have glass transition temperatures (Tg)
of 15 C or less and have a refractive index of at least 1.5, preferably at
least 1.52, where the inducible change in the refractive power is preferably
still at least 0.005 (AnD= 0.005).
The invention accordingly furthermore relates to a crosslinked copolymer
comprising a polymerised composition as described above or as preferably
described.
The invention accordingly furthermore relates to a crosslinked copolymer
consisting of a polymerised composition as described above or as prefera-
bly described.
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
-47 -
The reaction conditions of a free-radical polymerisation are adequately
known to the person skilled in the art in the area of polymer chemistry.
Owing to the special feature that the compounds of the formula (1) or pre-
ferred embodiments thereof, as described above, are generally hydro-
phobic, the miscibility of the components, in particular due to the presence
of the hydrophilic monomers, in the composition according to invention may
be limited. However, the person skilled in the art is capable of selecting the
initiator carefully and selecting the process in the case of a thermal process
with respect to the temperature so that a homogeneous copolymer forms.
In the case of an identified miscibility gap, the polymerisation temperature
should be selected so that it does not lie within the miscibility gap.
The person skilled in the art is capable of identifying an incompatibility of
the materials which could lead to a miscibility gap. He can, for example,
irradiate a composition according to the invention, as described above, by
means of a suitable light source and record UV/VIS spectra at various tem-
peratures. Suitable wavelengths are between 450 nm and 750 nm. If, for
example, the transmission is plotted against the temperature for a wave-
length of 450 nm, a miscibility gap is identified if the increase in the trans-
mission jumps. The jump in the transmission can be explained by a sudden
decrease in the density of the mixture when separation occurs. With the aid
of an experiment of this type, the person skilled in the art is able to select
the suitable temperature of the thermally induced free-radical polymerisa-
tion.
The invention therefore furthermore relates to a process for the preparation
of the crosslinked copolymer, as described above, characterised in that the
composition according to the invention, as described above comprising or
consisting of the components described or described as preferred, is pro-
vided and subsequently subjected to free-radical polymerisation, where the
polymerisation temperature to be selected in the case of the use of a ther-
mal free-radical initiator does not lie within a miscibility gap of the
materials
of the composition provided.
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
-48 -
The polymerisation, as described above, is preferably carried out without a
solvent.
The properties of the copolymer according to the invention as raw material
for the production of ophthalmological products can be determined by
standard methods, such as, for example, using refractometry with and with-
out irradiation. Glistening and water absorption is determined by incubating
the sample at a certain temperature and for a certain time, generating a
multifocus image and counting the vacuoles on this image. The vacuole
number is quoted standardised to the volume. The water absorption can be
determined, for example, from the mass difference before and after incuba-
tion in water. Techniques for the determination of the material property of
polymers are known in the prior art and are not restricted in any way. The
methods used for characterisation of the crosslinked copolymers according
to the invention are described in greater detail in the experimental part, but
should not be regarded as restrictive.
The invention furthermore likewise relates to the use of the composition, as
described above or as preferably described, or the use of the crosslinked
copolymer resulting from the polymerised composition, as described above
or as preferably described, for the production of a blank for an ophthalmo-
logical product, preferably for an ophthalmic lens or an ophthalmological im-
plant, particularly preferably for an intraocular lens.
The term blank can also be used synonymously with the term semifinished
product and describes products which, in their basic form, have been pro-
duced from a raw material or from raw materials to such an extent that the
requisite working steps for fabrication of the end product are considerably
reduced. In general, blanks are prefabricated to a certain dimension, are
geometrically specified, solid bodies and comply with certain standards and
certification measures. The term semifinished product known from the
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
-49 -
metal industry, arising from "semifinished product manufacturing", covers
not only products made from metals or metal alloys, but also made from
plastic and correspondingly also applies to the manufacture of medical
products, also including ophthalmological products.
The invention accordingly furthermore relates to an article comprising the
copolymer according to the invention or the polymerised composition
according to the invention, as described above or as preferably described.
The article accordingly as the same advantages that have been described
for the copolymer according to the invention. The statements above apply
correspondingly.
The article is not restricted in any way and is preferably a blank or the fin-
ished ophthalmological product, preferably an ophthalmic lens or an oph-
thalmological implant, particularly preferably an intraocular lens or a phakic
intraocular lens.
The invention accordingly furthermore relates to the article as described
above, selected from a blank for an ophthalmic lens or an ophthalmological
implant, an ophthalmological implant, or an ophthalmic lens.
The copolymer according to the invention or the polymerised composition
according to the invention, as described above, can be used without restric-
tion for ophthalmic lenses of any type, preferably intraocular lenses or
phakic lenses, both for the haptic and also for the central optical lens. The
material according to the invention can also be combined with further mate-
rials which are known for the production of ophthalmic lenses. This would
be the case, for example, if the haptic is intended to consist of a different
plastic to the central optical lens. The person skilled in the art in the area
of
the production of intraocular lenses is familiar with the requisite processing
steps for the production of the blank and the finished product.
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
- 50 -
The free-radical polymerisation of the composition according to the inven-
tion, as described above or as preferably described, can be carried out, for
example, in a polymerisation mould. Multifarious materials, moulds and
techniques are known in this respect. A corresponding example is
described in the experimental part.
The invention therefore furthermore relates to a process for the production
of an article, as described above or as preferably described, characterised
in that a composition according to the invention, as described above, is pro-
vided, a polymerisation is carried out and an article is shaped at the same
time or subsequently. The article can, for example, be produced by mould-
ing as a blank, which is further converted into the finished product, for
example the ophthalmic lens, as described above. The further manufactur-
ing steps by cutting methods are adequately known to the person skilled in
the art.
Even without further comments, it is assumed that a person skilled in the art
will be able to utilise the above description in the broadest scope. The pre-
ferred embodiments should therefore merely be regarded as descriptive
disclosure which is absolutely not limiting in any way.
Above and below, all temperatures are quoted in C.
The invention is explained in greater detail by the following examples, but
without being restricted thereto.
Examples
Example 1 ¨ Preparation of compounds A, B, C and D:
Compound A, corresponding to (M-23), 12-((2-oxo-3-(4-penty1-2-(trifluoro-
methyl)phenyl)-2H-chromen-7-yl)oxy)dodecyl acrylate:
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 51 -
o I-12C 0 12 ___ o 0
' _--
-----,%
0 /
F
F
CH,
F
Compound B, corresponding to (M-20), 124(2-oxo-3-(4-penty1-2-(trifluoro-
methoxy)pheny1)-2H-chromen-7-yl)oxy)dodecyl acrylate:
H2C,,Ti0-.,0 0 0
"12
0 /
0 CH3
)<F
F F
Compound C, corresponding to (M-42), 124(2-oxo-3-(4-penty1-2-(trifluoro-
methoxy)pheny1)-2H-chromen-7-ypoxy)dodecyl methacrylate:
i
0
I
o CH3
)< F
F F
Compound D, corresponding to (M-33), 11-(2-oxo-3-(4-penty1-2-(trifluoro-
methoxy)pheny1)-2H-chromen-7-yOundecyl acrylate:
..,y0-t__,,,0,0
H2C
ii 1
0 ,
1
o CH3
)< F F
F .
The preparation of the above-mentioned compounds A is depicted in
Schema 1, the preparation of compounds B and C is depicted in Schema 2
and the preparation of compound D is depicted in Schema 3:
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 52 -
Scheme 1:
H 0 0 0
CF3
OH Cl
OH Ac20 0
F F
0 pyridine, A
Cl
OH
OH
HO
3 mol-% Pd(OAc)2BrOH
HO 0 0 12
5 mol-% SPhos
2.1 eq. K3PO4 4.00 eq. K2CO3
toluene, A acetone, reflux,
over weekend
CI
HOC) 0 0
. 7
4.0 eq. Et3N
THF, 0 C to RT
overnight
0 0
= 7
Compound A
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
- 53 -
Scheme 2:
ocF3
N
Br =
HOAG exc.
NCI (25 wt.%) exc.
reflux, overnight
H 0 0 0
OCF3
OH OH Ac20 0
0 pyridine, A
Br F3C0 Br
OH
OH
1) 3 mol-% Pd(OAc)2
5 mol-% SPhos
2.1 eq. K3PO4
toluene, 90 C
HO 0 0 12
2) acidic workup 4.00 eq. K2CO3
acetone, reflux,
F3C0
over weekend
0
0 o
7
4.0 eq. Et3N
THF, 0 'C to RT
F3C0 overnight
0
OO 0 0
7
R = H, Me F3C0
Compound B
Or
Compound C
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 54 -
Scheme 3:
ocF3
Br =
HOAc exc.
HCI (25 wt.%) exc.
reflux, overnight
H 0 0 0
OCF3
alo OH OH Ac20 0
__________________________________ )
0 pyridine, A
Br F3C0 Br
OH
OH
HOB
1)3 mol-% Pd(OAc)2
5 mol-% SPhos
R 0 P
2.1 eq. K3PO4 F \S' F
toluene, 90 'C F) 0 0)<F
HO 0 0
2) acidic workup 1.3 equiv.
F3C0 DCM, 0 1C to it
5 mol-% Pd(PPh3)Cl2
0 1.5 mol-% Cul
0 Diisopropylamine (2.4 equiv.)
OCF3
THF, 50 'C
Tf0
1.2 equiv.
0
0 hydrogenation
Pd/C
OCF3
THE
HO
9
0
cI
0 0
4.0 eq. Et3N 0 , 0
__________________________________ )
OCF3 OCF3
THE, 0 1C to RI
overnight
HO,H.C".
0
Compound D
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 55 -
Example 2: Polymerisation
The monomers employed, as evident in Table 1 below, were purchased
commercially and employed without further purification.
General procedure:
A corresponding composition according to the invention, as described in
Table 1, is prepared in a flask by mixing the individual components and
degassed.
The polymerisation is carried out without a solvent. The polymerisation
mould consists in the interior of a silicone mat of suitable thickness, for
example a thickness between Ito 3 mm, from which the shape of the spec-
imen, for example a bar of 1 mm x 25 mm x 30 -70 mm, or of the corre-
spondingly desired blank, and a filling channel have been cut out, and two
glass plates, between which the silicone mat is laid. A separation layer, for
example a PET film, is in each case laid between glass plate and silicone
mat. The polymerisation conditions are selected depending on the initiator,
which are apparent to skilled personnel from the respective mixture compo-
sition. The amount of initiator is likewise indicated in Table 1. The polymeri-
sation temperature is between 70 C and 180 C.
C18MA = octadecyl methacrylate
HEMA = 2hydroxyethyl methacrylate
EGDMA = ethylene glycol dimethacrylate
UV abs = 243-(2H-benzotriazol-2-y1)-4-hydroxyphenyl]ethyl methacrylate
DtCyP = 1,1-bis(tert-butylperoxy)-3,3,5-trimethylcyclohexane
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 56 -
Table 1: Compositions - figures in equivalents, the photoactive monomer
corresponds to compound A:
1 2 3 4* 5* 6*
Comp. A 1.00 1.00 1.00 1.00 1.00 1.00
C18MA 0.15 0.15 0.15 0.15 0.15 0.15
HEMA 0.00 0.25 0.50 0.60 0.70 0.80
EGDMA 0.10 0.10 0.10 0.10 0.10 0.10
UV abs 0.01 0.01 0.01 0.01 0.01 0.01
DtCyP 0.02 0.02 0.02 0.02 0.02 0.02
7* 8 9 10
Comp. A 1.00 1.00 1.00 1.00
C18MA 0.15 0.15 0.15 0.15
HEMA 1.00 1.25 1.50 2.00
EGDMA 0.10 0.10 0.10 0.10
UV abs 0.01 0.01 0.01 0.01
DtCyP 0.02 0.02 0.02 0.02
The compositions according to the invention are denoted by an *.
The materials from the polymerisation of compositions Ito 10 in Table 1
are characterised using the following methods:
Refractometry
The refractive index nip is determined by means of a Schmidt-Haensch
model ATR-Lambda multiwave refractometer. The measurements are car-
ried out at 20 C.
Irradiation and refractive index change
A sample is covered with a borosilicate glass and irradiated by means of a
125 W Hg high-pressure lamp. The refractive index is determined between
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
- 57 -
the measurements. The irradiation is continued until a refractive index
change is no longer observed. The difference between the initial refractive
index and the refractive index after irradiation is referred to as Arlo.
Glistening (GT) water absorption (WA)
A sample with a thickness of 1 mm, for example a disc having a diameter of
9.5 mm and a thickness of 1mm, is incubated in water at 45 C for 24 h. The
sample is subsequently incubated in warm water at 37 C for a further 2.5 h.
The samples treated in this way are investigated by microscopy. A series of
images with various focal planes is recorded in dark field using a micro-
scope (M205 FA, Leica) fitted with a camera (DMC 4500, Leica). This is
joined together to form a multifocus image, and the vacuoles on this image
are counted. The vacuole number is quoted standardised to the volume.
The water absorption is determined from the mass difference before and
after incubation for 72 hours in water at 45 C or 30 C.
Table 2: Results: (n.d. = not determined)
1 2 3 4* 5* 6*
Appearance
after clear clear clear clear clear clear
polymerisation
nD 1.544 1.542 1.541 1.539 1.537 1.532
Ano 0.006 0.006 0.005 0.007 0.006 0.006
Appearance
cloudy cloudy cloudy clear clear clear
after GT test
Vacuoles/mm3 n.d. n.d. n.d. 9.0 3.9 10.8
Miyata scale n.d. n.d. n.d. 0 0 0
WA (45 C)/% 0 0 0.2 0.9 0.9 1.4
WA (30 C)/% 0.1 0.2 0.2 0.6 0.8 1.0
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
- 58 -
Continuation of Table 2:
7* 8 9 10
Appearance clear clear cloudy cloudy
after
polymerisation
nD 1.529 1.542 1.530 1.525
An) 0.006 0.003 0.005 0.004
Appearance clear cloudy cloudy cloudy
after GT test
Vacuoles/mm3 0.01 0.01 0.01 0.01
Miyata scale 8.5 n.d. n.d. n.d.
WA (45 C)/% 0 n.d. n.d. n.d.
WA (30 C)/% 1.6 3.6 3.0 4.2
WA (30 C)/% 1.6 2.7 3.3 3.9
The results of polymerised compositions Ito 10 (corresponding to copoly-
mers Ito 10) clearly show that, owing to the addition of the hydrophilic
component HEMA, good refractive index changes are still achieved, but no
opacification occurs in the glistening test when the amount of HEMA is
selected in accordance with the invention. The copolymer of polymerised
compositions 4, 5, 6, 7 is still clear after the polymerisation, furthermore
it
exhibits no opacification after glistening, i.e. virtually no glistening is
evident
and the vacuole number corresponds to degree 0 on the scale introduced
by Miyata.
Polymerised compositions 4 to 7 according to the invention are ideal. If all
material properties are considered together, polymerised composition 5 is
particularly preferred.
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
- 59 -
Example 3:
The following compositions are polymerised analogously to Example 2 and
measured in accordance with Example 2:
Table 3:
11* 12* 13* 14* 15* 16*
Compound A A B C D D
Amount of
1.00 1.00 1.00 1.00 1.00 1.00
compound
HEMA - - 0.60 0.60 0.80 0.60
HEA 0.56 0.6 - - - -
EGPEA 0.11 - - - - -
GDMA 0.1 0.1 0.1 0.1 0.1 0.1
UV abs 0.01 0.01 0.01 0.01 0.01 0.01
DtCyP 0.02 ' 0.02 0.02 0.02 0.02 0.02
Continuation of Table 3:
17* ' 18
Compound B B
Amount of 1.00 1.00
compound
HEMA 1.00 1.25
HEA
EGPEA
GDMA 0.1 0.1
UV abs 0.01 0.01
DtCyP 0.02 0.02
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642 PCT/EP2018/085433
- 60 -
The results are shown in Table 4:
Table 4:
11* 12* 13* 14* 15* 16*
Appearance
after clear clear clear clear clear clear
polymerisation
nD 1.548 1.547 1.544 1.542 1.538 1.537
AnD 0.007 0.003 0.022 0.019 0.013 0.012
Appearance
clear clear clear clear clear clear
after GT test
Vacuoles/mm3 15.3 10.8 2.2 17.4 13.6 7.1
Miyata scale 0 0 0 0 0 0
WA (45 C)/% 0.9 1.3 1.6 1.3 2.3 2.1
WA (30 C)/% 0.8 1.0 1.0 0.8 1.7 1.5
Continuation of Table 4:
17* 18
Appearance clear clear
after
polymerisation
nD 1.549 1.543
AnD 0.012 0.007
Appearance clear cloudy
after GT test
Vacuoles/mm3 1.4 n.b.
Miyata scale 0 n.b.
WA (45 C)/% 3.0 3.9
WA poocy% 2.6 3.5
Date Recue/Date Received 2020-06-19
CA 03086609 2020-06-19
WO 2019/121642
PCT/EP2018/085433
-61 -
The results of polymerised compositions 11 to 17 clearly show that, owing
to the addition of the hydrophilic component, good refractive index changes
are still achieved, but no opacification occurs in the glistening test if the
amount of hydrophilic component is selected in accordance with the inven-
tion.
15
25
Date Recue/Date Received 2020-06-19
